News

Presentations & Publications

COBRA™: A Highly Potent Conditionally Active T cell Engager Engineered for the Treatment of Solid Tumors

July 19, 2020 | mAbs

Maverick Therapeutics Jefferies Conference Corporate Overview

June 3, 2020 | Jefferies Virtual Healthcare Conference

An Exclusive Speaker Interview With Chad May, SVP of Research & Development at Maverick Therapeutics

March 30 – April 1, 2020 | Cell Engager Summit 2020

Maverick Therapeutics Corporate Presentation

Q1, 2020

Press Releases

Maverick Therapeutics Announces Key Executive Promotion and Scientific Advisory Board Appointments to Further Prepare for Clinical Development in 2021
August 31, 2020
Maverick Therapeutics Reveals Preclinical Data from COBRA™ Program, MVC-280, at Virtual Cell Engager Summit 2020
August 19, 2020
Maverick Therapeutics Announces First Peer-Reviewed Publication Describing the Design and Development of the COBRA™ Platform
August 6, 2020
Maverick Therapeutics Announces Pipeline Updates for its Conditionally Active T Cell Engaging COBRA™ Platform at the Jefferies Virtual Global Healthcare Conference
June 3, 2020
Maverick Therapeutics to Participate at 2020 Jefferies Virtual Healthcare Conference
May 27, 2020
Maverick Therapeutics Appoints Dr. Chulani Karunatilake as Senior Vice President of Technical Operations
July 30, 2019
Maverick Therapeutics To Unveil Pre-clinical Data On Novel COBRA™ Platform At American Association For Cancer Research 2019 Annual Meeting
March 30, 2019
Maverick Therapeutics Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline of Next Generation T Cell Therapeutics in Immuno-Oncology
January 29, 2019
Maverick Therapeutics Advances Technology; Adds Key Management
July 18, 2018
Maverick Therapeutics Appoints James S. Scibetta as CEO
August 10, 2017
Maverick Therapeutics and Takeda Announce Five-year Exclusive Collaboration to Advance T-Cell Engagement Therapies
January 11, 2017
Back To Top